Cabot Corporation (CBT) Fair Value 2026

CBT · Specialty Chemicals ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.6 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Cabot Corporation (CBT) trades at $84.58, versus a $67.78 median fair value across its 12 active models — 19.9% below the current price. QOC: 8.6/10. Value Trap Risk: 0/100 (SAFE). 12/13 models active. Within that set, the Bayesian DCF component alone returns $43.51.

Key Facts

Ticker
CBT
Price
$84.58
Quality Score
8.6/10
Value Trap Risk
0/100
Models Active
12/13
Last Updated
Strength: Quality Score of 8.6/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is Cabot Corporation (CBT) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, Cabot Corporation (CBT) appears overvalued as of : the median of 12 independent fair value estimates is $67.78, 19.9% below the current price of $84.58. Estimates range from $34.63 to $223.39. CBT scores 8.6/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CBT’s -19.9% gap is narrower than that market norm, and the Specialty Chemicals sector median is -35.9%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Cabot Corporation Stock in 2026? →

What Fair Value Does Each Model Give CBT?

12 Intrinsic Value Models vs. Current Price ($84.58)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $43.51 -48.6%
Intrinsic · High Conviction
 $35.43 -58.1%
Ensemble · Low Conviction
 $73.49 -13.1%
Intrinsic · High Conviction
 $51.67 -38.9%
Unlock the Full Matrix

Access 8 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is CBT's Fair Value Range?

Spread across 12 independent models · $34.63 to $223.39

CirclFi's 12 active models place Cabot Corporation (CBT) between $34.63 and $223.39 per share, a spread of 279% of the median. The median of that range — $67.78 — is the fair value CirclFi publishes for CBT, against a current price of $84.58.

Low · Dynamic NAVHigh · Regime Cross
$34.63median $67.78$223.39
Where the range comes from
Most bearish modelDynamic NAV$34.63
Most bullish modelRegime Cross-Sectional$223.39
Model agreement5 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CBT. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CBT, not a CirclFi price target. How each model works →

What Is Cabot Corporation (CBT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Cabot Corporation at its current price of $84.58. The median intrinsic value is estimated at $67.78 (-19.9% vs price), with 7 models flagging overvaluation risk. Notably, Regime Cross sees the most upside at +164.1% (fair value: $223.39), while Dynamic NAV is the most conservative at -59.1% ($34.63). The spread between these extremes — +223.2% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About CBT?

12 of 13 models are currently active for CBT. Of these, 5 models suggest upside while 7 models suggest overvaluation. Taken together, their median fair value for CBT is $67.78 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $43.51 on its own, implying -48.6% downside from the current price. See which stocks rank higher →

How Does CBT Rank in Specialty Chemicals?

Among 69 Specialty Chemicals stocks, CBT ranks #12 by Quality of Company score. CirclFi's QOC score of 8.6/10 evaluates 32 fundamental signals. A score of 8.6 places CBT in the top tier.

See all Most Undervalued Specialty Chemicals Stocks →

As a manufacturing company, Cabot Corporation operates in a sector where book-to-bill ratio is a critical driver of valuation. Investors evaluating CBT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CBT a Value Trap?

CirclFi's Value Trap algorithm assigns CBT a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Cabot Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Cabot Corporation is rated at 8.6/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.

The gap between the most bullish and bearish model spans +223.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CBT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CBT's 12 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cabot Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Specialty Chemicals Stocks Should You Also Analyze?

11 related Specialty Chemicals stocks with 13-model coverage

AXTAAxalta Coating Systems Ltd.QOC 8.6ESIElement Solutions IncQOC 8.6PPGPPG Industries, Inc.QOC 8.7NTICNorthern Technologies International CorporationQOC 8.2ECLEcolab Inc.QOC 8.7NGVTIngevity CorporationQOC 8.2ALBAlbemarle CorporationQOC 7.2NNUPNocopi Technologies, Inc.QOC 6.3BIOFBlue Biofuels, Inc.QOC 4.1ODCOil-Dri Corporation of AmericaQOC 9.2RPMRPM International Inc.QOC 9.0

Read investment analysis: AXTA · ESI · PPG · NTIC · ECL · NGVT · ALB · NNUP · BIOF · ODC · RPM

Which Other Stocks Have a Similar Quality Score to CBT?

7 companies across all industries closest to CBT’s Quality of Company score of 8.6/10.

ALGAlamo Group Inc.QOC 8.6MSCIMSCI Inc.QOC 8.6FRSHFreshworks Inc.QOC 8.6STGSunlands Technology GroupQOC 8.6REGRegency Centers CorporationQOC 8.6HPKHighPeak Energy, Inc.QOC 8.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ALG · MSCI · FRSH · STG · REG · HPK · NVDA

Where Does CBT Sit in CirclFi's Specialty Chemicals Rankings?

CBT is ranked against every other Specialty Chemicals stock CirclFi covers in each of these screens.

See all Specialty Chemicals stocks ranked →

What Else Do Investors Ask About Cabot Corporation’s Valuation?

What is Cabot Corporation's intrinsic value in 2026?

CirclFi puts Cabot Corporation (CBT)'s intrinsic value at $67.78 — the median of 12 independent model estimates as of 2026-08-27, ranging from $34.63 to $223.39. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $43.51 on its own. The Quality of Company score is 8.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CBT overvalued or undervalued right now?

At $84.58, 5 of 12 active models suggest CBT may be undervalued, while 7 indicate potential overvaluation. The median of all 12 fair value estimates is $67.78, 19.9% below the current price of $84.58 — a consensus view that CBT is overvalued. The assessment depends on which methodology best fits Cabot Corporation's business model in Specialty Chemicals.

What does a Quality of Company score of 8.6 mean for CBT?

Cabot Corporation's QOC of 8.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CBT?

CirclFi analyzes CBT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CBT?

Of the 12 models currently active on CBT, Regime Cross-Sectional is the most bullish at $223.39 per share, and Dynamic NAV is the most bearish at $34.63. CirclFi's published fair value for CBT is the median of that range, $67.78, not either extreme. The gap between the two ends equals 279% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CBT a value trap in 2026?

Cabot Corporation's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 12-model valuation engine, Cabot Corporation (CBT) has a median fair value of $67.78 — 19.9% below the current price of $84.58 — as of 2026-08-27.” Source: circlfi.com/stock/CBT/ · Methodology
Primary sources for this CBT valuation
  • Financial statements: Cabot Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000016040) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CBT as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on CBT.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

8 models hidden for CBT Unlock All 12 — $39/mo